WO2013141565A1 - 피부 방어력 증진용 조성물 - Google Patents

피부 방어력 증진용 조성물 Download PDF

Info

Publication number
WO2013141565A1
WO2013141565A1 PCT/KR2013/002233 KR2013002233W WO2013141565A1 WO 2013141565 A1 WO2013141565 A1 WO 2013141565A1 KR 2013002233 W KR2013002233 W KR 2013002233W WO 2013141565 A1 WO2013141565 A1 WO 2013141565A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
weight
extract
compound
Prior art date
Application number
PCT/KR2013/002233
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
김현정
나용주
김은혜
박성일
김연준
한상훈
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Priority to SG11201405279TA priority Critical patent/SG11201405279TA/en
Priority to CN201380014884.XA priority patent/CN104203249B/zh
Publication of WO2013141565A1 publication Critical patent/WO2013141565A1/ko
Priority to HK14113061.1A priority patent/HK1199410A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9755—Gymnosperms [Coniferophyta]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a composition for enhancing skin defense.
  • the present invention seeks to provide a composition capable of enhancing skin defenses.
  • One aspect of the present invention provides a composition for enhancing skin defenses comprising at least one of a Protopanaxadiol-based compound and a Toya nucifera extract as an active ingredient.
  • Another aspect of the present invention is one or more of a protopananaxadiol-based compound and a non-extract extract; And epigallocatechin gallate as an active ingredient.
  • composition according to the present invention comprises at least one of a protoparanaxadiol-based compound and a visa extract; And optionally epigallocatechin gallate, thereby promoting the antimicrobial peptide activity of the skin to promote the skin's own defenses without irritating the skin can exhibit excellent skin antibacterial and anti-inflammatory activity.
  • Figure 1 is a graph comparing the effect of compound K, visaza oil, epigallocatechin gallate and mixtures thereof and tea tree oil on the skin antimicrobial peptide expression, respectively.
  • the term “skin” refers to a tissue covering the body surface of an animal, and is a broad concept including not only tissues covering the body surface such as the face or body, but also the scalp and hair.
  • extract is a broad concept including all substances obtained by extracting a component of a natural product, regardless of the extraction method, the extraction solvent, the extracted component or the form of the extract, and examples thereof include oil components extracted from natural products.
  • skin defense is the ability to protect the skin from external stimuli, toxins, and the stimulus is a broad concept that includes all of the harmful stimuli to the skin such as bacteria, viruses, ultraviolet light, dryness, wounds and the like.
  • the substance promoting the antimicrobial peptide activity of the skin will be able to enhance the antimicrobial and anti-inflammatory activity of the skin by enhancing the defense of the skin itself without irritating the skin.
  • compositions for enhancing skin defenses comprising at least one of a protoparanaxadiol-based compound and a non-extract extract as an active ingredient.
  • Protoparnaxadiol-based compounds or non-extract extracts may promote skin defense by promoting antimicrobial peptide expression on the skin. Therefore, the composition comprising at least one of the protopanaxadiol-based compound and the non-extract extract can enhance skin defense, specifically skin antibacterial and anti-inflammatory activity, and further improve skin troubles including acne.
  • the antimicrobial peptide is a peptide that acts to suppress invading pathogens induced by expression when external stimulation, hBD1, hBD2, LL37 or Rnase7 and the like as a representative example, but is not limited thereto. no.
  • the Protopanaxadiol-based compound is a kind of ginsenoside which is ginseng saponin.
  • the protoparanaxadiol-based compound may be obtained by enzymatic treatment of ginseng, specifically red ginseng.
  • the protoparanaxadiol-based compound includes compound K (compound K).
  • Compound K is 20-O- (beta-D-glucopyranosyl) -20 (S) -protopanaxadiol (20-O- (beta-D-glucopyranosyl) -20 (S)-, also called ginsenoside M1.
  • protopanaxadiol can be represented by the following formula.
  • the composition according to one aspect of the present invention is 0.001% to 10% by weight, specifically 0.01% to 5% by weight, more specifically 0.1% to 3% by weight of the protopanaxadiol compound based on the total weight of the composition It may include.
  • the above range is not only suitable for showing the intended effect of the present invention, it can satisfy both the stability and safety of the composition, it may be appropriate to include in the above range in terms of cost-effectiveness.
  • the composition contains less than 0.001% by weight of the protopanaxadiol-based compound, the skin defense enhancement effect may be insignificant, and when it contains more than 10% by weight, the solubility of the protopanaxadiol-based compound in the solvent is lowered.
  • the stability of the composition may be lowered.
  • the visa extract comprises an extract of Visa, specifically the extract of Visa, which is the fruit of the Torreya nucifera .
  • the visa extract comprises a non-oil oil, specifically a non-seed oil, which is a fat or oil component obtained by compressing the visa or extracting with an organic solvent.
  • the organic solvent may include one or more selected from the group consisting of alcohol, hexane, acetone, ethyl acetate, diethyl ether, ethyl methyl ketone, and chloroform, but is not limited thereto.
  • the composition may comprise 0.001% to 99% by weight, specifically 0.1% to 80% by weight, more specifically 10 to 50% by weight, based on the total weight of the composition.
  • the above range is not only suitable for showing the intended effect of the present invention, it can satisfy both the stability and safety of the composition, it may be appropriate to include in the above range in terms of cost-effectiveness.
  • the skin defense enhancement effect may be insignificant.
  • composition for enhancing skin defense may further include Epigallocatechin Gallate.
  • composition for enhancing skin defenses according to the present invention may further include epigallocatechin gallate, thereby having a higher skin antibacterial and anti-inflammatory activity, and thus having a better skin defense enhancing effect.
  • Epigallocatechin Gallate is a catechin mainly contained in green tea, which is a kind of polyphenol, and may be represented by the chemical formula of (-)-Epigallocatechin-3-gallate.
  • epigallocatechin gallate can be obtained by extracting green tea.
  • the composition according to one aspect of the present invention is from 0.00001% to 10% by weight, specifically from 0.0001% to 5% by weight, more specifically from 0.001% to 1% by weight of epigallocatechin gallate It may include.
  • it can satisfy both the stability and safety of the composition, it may be appropriate to include in the above range in terms of cost-effectiveness.
  • the skin defense enhancement effect may be insignificant, and when it contains more than 10% by weight, oxidation may occur and it may be difficult to secure the stability of the formulation. have.
  • One aspect of the present invention is at least one of a protopananaxadiol-based compound and a visa extract; And optionally epigallocatechin gallate as an active ingredient.
  • the cosmetic composition may exhibit a skin defense enhancement effect, specifically may exhibit excellent antibacterial and anti-inflammatory activity, and may further improve or prevent skin troubles including skin acne.
  • Cosmetic compositions according to the invention may be provided in all formulations suitable for topical application.
  • it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a foam, or an aerosol composition.
  • Compositions of such formulations may be prepared according to conventional methods in the art.
  • the cosmetic composition according to the present invention may further include a moisturizer, an emulsifier, a surfactant, a ultraviolet absorbent, a preservative, a fungicide, an antioxidant, a pH adjuster, organic and inorganic pigments, flavors, coolants, or limiting agents.
  • a moisturizer an emulsifier, a surfactant, a ultraviolet absorbent, a preservative, a fungicide, an antioxidant, a pH adjuster, organic and inorganic pigments, flavors, coolants, or limiting agents.
  • the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition have.
  • One aspect of the present invention is at least one of a protopananaxadiol-based compound and a visa extract; And optionally epigallocatechin gallate as an active ingredient.
  • the pharmaceutical composition may exhibit a skin defense enhancing effect, specifically may exhibit excellent antibacterial and anti-inflammatory activity, and may further treat or improve skin troubles including skin acne.
  • composition according to one aspect of the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous.
  • Formulations for oral administration may be tablets, pills, soft and hard capsules, granules, powders, fine granules, solutions, emulsions or pellets, but are not limited thereto. It is not. These formulations may contain, in addition to the active ingredient, diluents (e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine), glidants (e.g. silica, talc, stearic acid or polyethylene glycol), or binders (e.g. magnesium aluminum Silicates, starch pastes, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpyrrolidone). It may optionally contain pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, or sweeteners.
  • the tablets can be prepared by conventional mixing, granulating or coating methods.
  • Formulations for parenteral administration may be, but are not limited to, injections, drops, lotions, ointments, gels, creams, suspensions, emulsions, suppositories, patches or sprays.
  • the active ingredient of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Dosage determination based on these factors is within the level of one skilled in the art and its daily dosage may be, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / kg. May be, but is not limited to.
  • Compound K was obtained by hydrolyzing red ginseng with an enzyme.
  • Visa seed oil was obtained by pressing seed of Visa or extracting with organic solvent.
  • Epigallocatechin gallate was obtained by the following method. First, the green tea leaves (dry moisture content of 3% or less) were extracted with reflux of hot water at 30-70 ° C. for 1 hour to 24 hours with 10 times purified water, followed by primary filtration to remove the residue, and the remaining filtrate was filtered again. The water soluble component was separated. Only epigallocatechin gallate of the separated water-soluble components was selectively precipitated, concentrated through a crystallization reaction, and the filtrate not precipitated was removed by filtration. The precipitate was decomposed again, purified by chromatography, and the solvent was evaporated to yield epigallocatechin gallate of high purity.
  • compound K, visaseed oil, epigallocatechin gallate (EGCG), compound K and visaseed oil, compound K, visaseed oil and EGCG are skin antibacterial peptides hBD1, hBD2, LL37, Rnase7
  • tea tree oil a raw material frequently used in antibacterial cosmetics among natural substances, inhibited the expression of all four genes. That is, while tea tree oil cannot enhance the skin's own defense, compound K, visase oil, epigallocatechin gallate (EGCG) and mixtures thereof activate the skin's antimicrobial peptides to protect the skin's defense itself. It can be seen that it can be enhanced.
  • the lotion is prepared according to a conventional method with the composition shown in the table below.
  • Compound K 1.0 Visa seed oil 5.0 L-ascorbic acid-2-magnesium phosphate 1.0 Water Soluble Collagen (1% Aqueous Solution) 1.0 Sodium citrate 0.1 Citric acid 0.05 1,3-butylene glycol 3.0 Purified water Remaining amount
  • a cream is prepared according to a conventional method with the composition described in the table below.
  • Table 4 ingredient Content (% by weight) Visa extract 20.0 Polyvinyl alcohol 13.0 L-ascorbic acid-2-magnesium phosphate 1.0 Lauroylhydroxyproline 1.0 Water Soluble Collagen (1% Aqueous Solution) 2.0 1,3-butylene glycol 3.0 ethanol 5.0 Purified water Remaining amount
  • a soft capsule is prepared according to a conventional method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
PCT/KR2013/002233 2012-03-20 2013-03-19 피부 방어력 증진용 조성물 WO2013141565A1 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SG11201405279TA SG11201405279TA (en) 2012-03-20 2013-03-19 Composition for enhancing defenses of skin
CN201380014884.XA CN104203249B (zh) 2012-03-20 2013-03-19 用于增强皮肤防御能力的组合物
HK14113061.1A HK1199410A1 (zh) 2012-03-20 2014-12-30 用於增强皮膚防禦能力的組合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2012-0028321 2012-03-20
KR1020120028321A KR101902244B1 (ko) 2012-03-20 2012-03-20 피부 방어력 증진용 조성물

Publications (1)

Publication Number Publication Date
WO2013141565A1 true WO2013141565A1 (ko) 2013-09-26

Family

ID=49222955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/002233 WO2013141565A1 (ko) 2012-03-20 2013-03-19 피부 방어력 증진용 조성물

Country Status (6)

Country Link
KR (1) KR101902244B1 (zh)
CN (1) CN104203249B (zh)
HK (1) HK1199410A1 (zh)
SG (1) SG11201405279TA (zh)
TW (1) TWI597068B (zh)
WO (1) WO2013141565A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105520869B (zh) * 2014-10-21 2020-08-04 株式会社韩国人参公社 含有红参浓缩液的粉刺改善用组合物
KR102081204B1 (ko) * 2016-09-08 2020-02-25 (주)아모레퍼시픽 탈수소 아비에틱산 및 컴파운드 k를 포함하는 피부 항노화용 조성물
KR101861579B1 (ko) * 2017-10-11 2018-05-28 경성대학교 산학협력단 컴파운드 k를 유효성분으로 포함하는 각결막염 예방 또는 치료용 약학 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175315A1 (en) * 2002-01-05 2003-09-18 Yoo Byung Hee Nanoemulsion comprising metabolites of ginseng saponin as an active component and a method for preparing the same, and a skin-care composition for anti-aging containing the same
KR20050038381A (ko) * 2003-10-22 2005-04-27 한불화장품주식회사 금등화 추출물 또는 비자 추출물로부터 선택된 1종 이상을주요 활성성분으로 함유하는 피부외용제 조성물
KR20080101419A (ko) * 2007-05-18 2008-11-21 (주)아모레퍼시픽 녹차꽃 추출물을 함유하는 피부용 외용제 조성물
KR20090087709A (ko) * 2008-02-13 2009-08-18 주식회사 한국인삼공사 사포닌을 유효성분으로 포함하는 치주질환의 치료용 조성물
KR20110054154A (ko) * 2009-11-17 2011-05-25 (주)아모레퍼시픽 비자나무의 미성숙 열매 또는 종자 추출물을 함유하는 화장료 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101601632B (zh) * 2009-06-16 2012-02-22 苏州和茂生物技术有限公司 包括20(s)-原人参二醇的组合物在制备用于护理皮肤的化妆品方面的应用
JP5563285B2 (ja) * 2009-12-14 2014-07-30 ライオン株式会社 飲食品、医薬品、又は医薬部外品、並びに、プロトパナキサトリオールの安定化方法、及びプロトパナキサジオールの安定化方法
CN102743402B (zh) * 2012-07-15 2014-06-04 浙江大学 人参二醇皂苷组分在制备防治皮炎和疤痕药物中的用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175315A1 (en) * 2002-01-05 2003-09-18 Yoo Byung Hee Nanoemulsion comprising metabolites of ginseng saponin as an active component and a method for preparing the same, and a skin-care composition for anti-aging containing the same
KR20050038381A (ko) * 2003-10-22 2005-04-27 한불화장품주식회사 금등화 추출물 또는 비자 추출물로부터 선택된 1종 이상을주요 활성성분으로 함유하는 피부외용제 조성물
KR20080101419A (ko) * 2007-05-18 2008-11-21 (주)아모레퍼시픽 녹차꽃 추출물을 함유하는 피부용 외용제 조성물
KR20090087709A (ko) * 2008-02-13 2009-08-18 주식회사 한국인삼공사 사포닌을 유효성분으로 포함하는 치주질환의 치료용 조성물
KR20110054154A (ko) * 2009-11-17 2011-05-25 (주)아모레퍼시픽 비자나무의 미성숙 열매 또는 종자 추출물을 함유하는 화장료 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOON, W. J. ET AL.: "Torreya nucifera essential oil inhibits skin pathogen growth and lipopolysaccharide-induced inflammatory effects", INTERNATIONAL JOURNAL OF PHARMACOLOGY, vol. 5, no. 1, 2009, pages 37 - 43 *

Also Published As

Publication number Publication date
CN104203249A (zh) 2014-12-10
KR101902244B1 (ko) 2018-10-01
TWI597068B (zh) 2017-09-01
HK1199410A1 (zh) 2015-07-03
TW201340991A (zh) 2013-10-16
KR20130106627A (ko) 2013-09-30
SG11201405279TA (en) 2014-11-27
CN104203249B (zh) 2018-04-24

Similar Documents

Publication Publication Date Title
WO2010011020A1 (en) Method for preparing polysaccharide of green tea and cosmetic composition for skin whitening, moisturization and anti-wrinkle effects comprising the polysaccharide
KR101932668B1 (ko) 쉬나무 추출물을 유효성분으로 하는 창상 치유용 약학 조성물
KR20110073570A (ko) 강심 배당체의 추출방법 및 조성물
WO2012067404A2 (ko) 청호쑥 추출물을 유효성분으로 함유하는 항노화용 조성물
WO2010062103A2 (ko) 피부외용 조성물 및 그 제조방법
WO2013180526A1 (ko) 에델바이스 추출물을 포함하는 피부 재생 및 모발 성장 촉진제
WO2018174453A1 (ko) 엉겅퀴 추출물을 유효성분으로 포함하는 멜라닌 생성 촉진용 조성물
WO2012002782A2 (ko) 닥나무의 꽃과 열매 추출물을 함유하는 피부 미백용 피부 외용제 조성물
WO2013141565A1 (ko) 피부 방어력 증진용 조성물
WO2022181936A1 (ko) 피부 유래 엑소좀을 통해 근손실 억제 또는 근생성 촉진 효과를 나타내는 조성물
WO2010058982A2 (en) Antioxidant cosmetic composition containing extract of processed peony, polygonati rhizoma or lily
WO2011065799A2 (ko) 차수 제조 방법 및 그에 의해 수득된 차수
WO2023249393A1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
KR20140025239A (ko) 복분자 뿌리의 활성분획물을 함유하는 화장료 조성물
WO2018111042A2 (ko) 한약재 추출물을 유효성분으로 포함하는 화장료 조성물
WO2023249392A1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
WO2020111621A1 (ko) 탈모 또는 피부 염증 억제용 조성물
WO2020091295A1 (ko) 저근백피 추출물을 유효성분으로 함유하는 여드름성 피부 개선용 또는 피지 분비 억제용 조성물
WO2016171482A1 (ko) 봉독 추출물을 포함하는 화장료 조성물 및 이의 제조방법
WO2020096240A1 (ko) 글루타치온에 특이적으로 결합하는 dna 압타머 및 그의 용도
WO2018194261A1 (ko) 4'-o-메틸알피눔 이소플라본의 치료적 용도
WO2015130131A1 (ko) 카테킨 프리 차수 및 이를 포함하는 조성물
WO2015126226A1 (ko) 녹차 잎자루 유래 추출물을 함유하는 피부 미백용 조성물
WO2021145672A1 (ko) 알지닌 아스파테이트를 포함하는 노인성 체취 억제용 조성물
WO2016093474A1 (ko) 면역 조절제 및 글루코사민을 포함하는 건선 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13764447

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 30-01-2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13764447

Country of ref document: EP

Kind code of ref document: A1